Lymphoma Medical Services in China

Lymphoma is a heterogeneous group of hematologic malignancies originating from lymphoid tissue—primarily B-cells, but also T-cells and natural killer (NK) cells. Classified broadly into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), it encompasses over 100 distinct subtypes with varying clinical behaviors, prognoses, and therapeutic requirements. Diagnosis relies on integrated assessment including histopathology, immunohistochemistry, flow cytometry, molecular profiling (e.g., MYC, BCL2, BCL6 rearrangements), and advanced imaging such as PET-CT. Treatment strategies are risk-adapted and may include immunochemotherapy (e.g., R-CHOP), targeted agents (e.g., rituximab, brentuximab vedotin, BTK inhibitors), radiotherapy, autologous or allogeneic hematopoietic stem cell transplantation, and emerging modalities like CAR-T cell therapy. Prognosis depends heavily on subtype, stage, IPI (International Prognostic Index) score, and molecular biomarkers.

China offers compelling advantages for lymphoma care: leading oncology centers—many accredited by JCI or ISO—employ multidisciplinary tumor boards with internationally trained hematologists and radiation oncologists. State-of-the-art infrastructure includes next-generation sequencing platforms, digital PET-CT, linear accelerators with VMAT/IMRT, and GMP-certified CAR-T manufacturing facilities. Five-year overall survival for diffuse large B-cell lymphoma exceeds 75% in top-tier hospitals, with robust real-world evidence supporting outcomes comparable to Western benchmarks. Crucially, treatment costs—including diagnostics, biologics, and transplant—are typically 40–60% lower than in the US or Western Europe, without compromising quality or regulatory compliance.

As a dedicated medical tourism agency, we facilitate seamless access for international patients: vetting accredited hospitals, coordinating specialist consultations, managing visa support and accommodation, ensuring transparent, all-inclusive pricing, and providing bilingual case management from diagnosis through follow-up.

Treatment Options & Itemized Cost Breakdown: Lymphoma (Hematology/Oncology)

Non-Surgical/Medical Therapies

*Indicated for most lymphomas (DLBCL, FL, MCL, HL), based on histology, stage, IPI score, and molecular markers.*

• •First-Line Chemotherapy (R-CHOP)

- *Eligibility:* Fit patients with aggressive B-cell lymphoma (e.g., DLBCL)

- *Cost per cycle (USD):* $1,850–$2,300 - Rituximab (375 mg/m²): $1,120 - Cyclophosphamide, Doxorubicin, Vincristine, Prednisone: $480 - Infusion & nursing: $250

• •Targeted Therapy (BTK Inhibitors – e.g., Ibrutinib)

- *Eligibility:* Relapsed/refractory CLL/SLL or MCL; confirmed *BTK* mutation

- *Monthly cost (USD):* $3,900–$4,200 (oral, 28-day supply)

• •Immunomodulatory Agents (Lenalidomide)

- *Eligibility:* R/R FL or MCL, ineligible for intensive chemo

- *Monthly cost (USD):* $2,600–$2,900

• •Diagnostic & Monitoring Labs/Exams (per cycle or baseline)

- PET-CT (whole-body): $680

- Bone marrow biopsy + flow cytometry: $410 - LDH, CBC, comprehensive metabolic panel: $125 - Serum free light chains & immunofixation: $190

Surgical/Procedural/Interventional Options

*Surgery is rarely curative but used diagnostically or for palliation in specific scenarios.*

• •Diagnostic Lymph Node Excisional Biopsy

- *Eligibility:* Suspicious peripheral or accessible nodal mass; insufficient core biopsy

- *Procedure cost (USD):* $1,450–$1,750 - OR time, anesthesia, pathology (H&E + IHC + molecular): $1,220 - Surgeon fee: $230

• •Debulking Surgery (Rare)

- *Eligibility:* Symptomatic bulky mediastinal or GI lymphoma causing obstruction/bleeding unresponsive to urgent chemo

- *Cost (USD):* $4,800–$6,200 - Pre-op workup (EKG, chest X-ray, coagulation panel): $180 - OR, anesthesia, ICU monitoring (1 day): $4,620

Special/Complex Condition Management

• •Autologous Stem Cell Transplant (ASCT)

- *Eligibility:* Fit patients with chemosensitive relapsed aggressive lymphoma or high-risk first remission

- *Total cost (USD):* $28,500–$34,000 - Mobilization (G-CSF + plerixafor): $3,200 - Apheresis & cryopreservation: $2,100 - Conditioning (BEAM or TBI-based): $11,800 - Transplant admission (14–21 days): $11,400

• •CAR-T Therapy (e.g., Relma-cel)

- *Eligibility:* R/R LBCL after ≥2 lines, confirmed CD19+ expression

- *Cost (USD):* $128,000–$142,000 (includes leukapheresis, manufacturing, infusion, 30-day monitoring)

Quick Selection Guide

• •<60 years, fit, newly diagnosed DLBCL: Start R-CHOP ($1,850/cycle × 6 = ~$11,100); add PET-CT ($680) for interim response assessment.
• •>75 years or frail with FL: Rituximab monotherapy ($1,120/cycle × 4 = $4,480) + lenalidomide ($2,600/month × 6 = $15,600) — lower toxicity, moderate budget.
• •Relapsed DLBCL, high IPI, budget >$100K: CAR-T ($128K+) offers best long-term remission odds.
• •R/R MCL with *TP53* mutation: Prioritize BTK inhibitor ($3,900/month) over ASCT due to poor transplant outcomes.
• •Bulky symptomatic mass with airway compromise: Urgent excisional biopsy + debulking ($4,800–$6,200) followed by bridging chemo.